Creative Biolabs is a global leader in antimicrobial resistance drug development, providing comprehensive services throughout the drug development cycle-from target identification and validation, hit identification, hit to lead, lead optimization to final drug discovery. Our capabilities as an integrated service provider and our experience in various technologies enable us to provide quality services to customers worldwide.
Haemophilus influenzae (H. influenzae) are small, pleomorphic, gram-negative coccobacillus that commonly colonizes and infect the human respiratory tract. The H. influenzae species can be divided into typeable (encapsulated) and nontypeable (unencapsulated) strains. Typeable strains possess a polysaccharide capsule, and these strains are serotyped into 6 different types (a-f) based on distinct polysaccharide antigens on their capsular surfaces. Among typeable strains, H. influenzae serotype b (Hib) is the most virulent and has historically accounted for the majority of cases of invasive disease. In areas of the world where Hib vaccination is not widespread, Hib is a leading cause of meningitis and epiglottitis in children and pneumonia in adults. However, due to the widespread use of Hib-conjugated vaccines, the incidence of invasive Hib diseases has greatly decreased. Nontypeable strains have no capsule and are therefore referred to as nonencapsulated H. influenzae or nontypeable H. influenzae (NTHi). Nontypeable strains are generally less virulent than Hib and most commonly cause infections along the respiratory mucosa.
Since the late 1970s, antibiotic resistance has gradually increased among H. influenzae strains, mainly in terms of β-lactam antibiotics, especially aminopenicillins and cephalosporins, which have caused a serious clinical concern all over the world. The most common mechanism of resistance to these agents is the production of β-lactamase - an enzyme, which inactivates these antibiotics. In clinical strains of H. influenzae, TEM and ROB β-lactamases have been identified. Other mechanisms of resistance to β-lactams are mutations in the ftsI gene, which encodes penicillin-binding proteins PBP3A and PBP3B. These mutations lead to alterations in PBP3A and PBP3B and reduce their affinity to β-lactam antibiotics. Strains that are resistant to β-lactams through this mechanism are called Beta-Lactamase Negative (or Non-producing), Ampicillin Resistant (BLNAR).
Because bacterial resistance to existing antibiotics is one of the biggest threats to public health and our healthcare systems, the development of new antibiotics and alternative therapies is critical to the global fight against antibacterial resistance. Creative Biolabs is a drug research and development company dedicated to developing the next generation of life-saving drugs. We provide comprehensive drug development services to help customers address complex drug development challenges and bring more products to market faster. The drug development services we offer include:
At Creative Biolabs, our focus is on serving as a "customer-centric" organization. We do this by putting customer’s needs at the heart of our mission. We are constantly improving our technology, strengthening communication with customers and meeting every need of customers to continue to provide the best service to our customers. If you are interested in our services, please feel free to contact us.
For Research Use Only.
